Cost-Effectiveness of Carrier Screening for Cystic Fibrosis in Australia
dc.contributor.author | Norman, Richard | |
dc.contributor.author | Van Gool, K. | |
dc.contributor.author | Hall, J. | |
dc.contributor.author | Delatycki, M. | |
dc.contributor.author | Massie, J. | |
dc.date.accessioned | 2017-01-30T12:50:09Z | |
dc.date.available | 2017-01-30T12:50:09Z | |
dc.date.created | 2015-07-16T06:21:52Z | |
dc.date.issued | 2012 | |
dc.identifier.citation | Norman, R. and Van Gool, K. and Hall, J. and Delatycki, M. and Massie, J. 2012. Cost-Effectiveness of Carrier Screening for Cystic Fibrosis in Australia. Journal of Cystic Fibrosis. 11: pp. 281-287. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/25772 | |
dc.identifier.doi | 10.1016/j.jcf.2012.02.007 | |
dc.description.abstract |
Background: Carrier screening for cystic fibrosis is not widely available in Australia, partly due to concerns regarding its cost-effectiveness. The benefit of information from pregnancy to pregnancy has not been widely considered in existing cost-effectiveness analyses.Methods: A decision tree was constructed estimating costs and outcomes from screening, including both initial and subsequent pregnancies. Effectiveness was expressed in terms of CF births averted. Costs were collected using a health service perspective. All costs and outcomes were discounted at 5% per annum.Results: Screening reduced the annual incidence of CF births from 34 to 14/100,000 births (an aggregate number of CF births of 100.9 and 41.9 respectively). In initial pregnancies, costs in the screening arm (A$16.6 million/100,000 births) exceed those in the non-screening arm (A $13.4 million/100,000 births). The incremental cost per CF birth in initial pregnancies is therefore approximately A$150,000. However, this was reversed for subsequent pregnancies, in that the pre-collected information reduces the incidence of CF in subsequent pregnancies at low additional costs.When aggregated, the results suggest screening is likely to be cost-saving.Conclusions: The introduction of national carrier screening for cystic fibrosis should be considered, as it is likely to reduce CF incidence at an acceptable (potentially negative) cost. | |
dc.publisher | Elsevier | |
dc.subject | Screening | |
dc.subject | Cost-effectiveness | |
dc.subject | Australia | |
dc.subject | Economic evaluation | |
dc.subject | Cystic fibrosis | |
dc.title | Cost-Effectiveness of Carrier Screening for Cystic Fibrosis in Australia | |
dc.type | Journal Article | |
dcterms.source.volume | 11 | |
dcterms.source.startPage | 281 | |
dcterms.source.endPage | 287 | |
dcterms.source.issn | 1569-1993 | |
dcterms.source.title | Journal of Cystic Fibrosis | |
curtin.accessStatus | Open access via publisher |